论文部分内容阅读
目的观察舒利迭吸入治疗慢性阻塞性肺疾病(COPD)稳定期患者的疗效。方法将70例处于稳定期的中、重度COPD患者,随机分为治疗组和对照组。两组均给予常规治疗,在此基础上,治疗组给予吸入舒利迭(50/250),每次1吸,每天2次;对照组给予缓释茶碱片,每次0.1 g,每天2次,比较两组治疗前、后肺功能及临床症状积分变化。结果治疗后治疗组肺功能指标、临床症状积分改善情况均明显优于对照组(P<0.05)。结论对于稳定期COPD患者,舒利迭能减轻临床症状,明显改善肺功能,提高生活质量。
Objective To observe the efficacy of seretide inhalation in patients with stable chronic obstructive pulmonary disease (COPD). Methods Seventy patients with moderate and severe COPD in stable phase were randomly divided into treatment group and control group. On the basis of this, the treatment group was given inhaled seretide (50/250) once a day for 2 times a day, while the control group was given sustained-release theophylline tablets (0.1 g per day for 2 days) Times, comparing the two groups before and after treatment, lung function and clinical symptom score changes. Results After treatment, the improvement of pulmonary function indexes and clinical symptom scores in the treatment group were significantly better than those in the control group (P <0.05). Conclusion For patients with stable COPD, seretide can relieve clinical symptoms, significantly improve lung function and improve quality of life.